Global Atherectomy and Thromboctomy Devices Market By Technology 2023

Atherectomy is one of the important peripheral arterial disease treatment, in which, atherosclerosis from large blood vessels are removed by using minimally invasive surgical approach. In addition, this technique is used for the treatment of coronary arterial diseases. Thromboctomy, also known as pulmonary thromboctomy, is an emergency medical treatment, by which thrombus (blood clot) is removed from arteries and veins. Thromboctomy can be performed by two technologies, by using surgery or by percutaneous techniques. However, surgical thromboctomy technique is used rarely, due to less efficient results and high cost.

Download Complete Healthcare Analytical Brochure: 
http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=4584

Atherectomy technique is a popular substitute for stents and angioplasty treatment. In case of latter, the deposited plaque is pushed inside blood vessel, however, in former, the plaque is removed by using surgical or mechanical technique. This technique has certain advantages over angioplasty and stents, such as, increased wound healing rate, reduction in claudication, reduction in threat of cardiac and other medical complications, less invasive nature, faster patient recovery, high repeatability, ease-of-performance and many others. The device is inserted in the body by making small incision to certain locations of body, such as, common femoral artery, political artery, bronchial artery and others.

The market of Atherectomy devices is segmented on the basis of type and mechanism of device functions, such as, orbital, laser, rotational and directional devices. However, preference of device is based on factors such as, nature and size of plaque, anatomical place to be treated, and surgeon’s expertise. The market for thromboctomy is also segmented on the basis of device type, such as, rotational, ultrasound enhanced and rheolytic thromboctomy devices. In addition, the market is segmented on the basis of geography, such as, North America, Europe, Asia-Pacific and Rest of the World (RoW). At present, the North American region is the most prominent market, owing to increasing technological intervention in cardiac disease management. However, Asia-Pacific and some countries in RoW region are expected to show very lucrative growth in the upcoming period, owing to enhanced awareness and growth in prevalence of cardiac patients and technologies.

The market for atherectomy and thromboctomy devices is expected to grow in the upcoming future at a lucrative rate, due to various market drivers, such as rapid increase in the cardiac diseases, changed life-style, increasing preference towards less invasive cardiac disease management practices, less risks involved in the procedure, decreased use of surgical practices for cardiac diseases treatment and technological growth in the development of advanced devices. Rising prevalence of cardiac disorders is one of the most important market driver. According to the U.S. Center for Disease Control and Prevention (CDC), around 0.6 million of Americans die every year due to cardiac diseases, and around 720,000 Americans have a heart attack every year. Further, changed life-style is another contributor for the market growth. Due to consumption of junk food, addiction and lack of exercise, the prevalence of cardiac diseases have been increased and it contributes the market growth of Atherectomy and thromboctomy devices. On the contrary, major restraints that impose hurdles in the market growth include high cost, limited awareness in certain region of the world. Key opportunities include development of cost-effective therapy and strong focus on APAC region (since, India and China possess the largest number of cardiac patients).

Some of the major players operating in the market include Bayer AG, Cardiovascular Systems, Inc., St. Jude Medical Inc., Boston Scientific Corporation, C.R. Bard, inc., Teleflex Medical Inc., and Covidien, Inc. among others.

Browse Full Research Report on Atherectomy and Thromboctomy Devices Market:
http://www.transparencymarketresearch.com/atherectomy-thromboctomy-devices-market.html

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We have an experienced team of Analysts, Researchers, and Consultants, who us e proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

North America Porcine Vaccine Market to US$926.2 Million by 2024

North America Porcine Vaccine Market: Snapshot

For several decades, vaccination has remained one of the most important interventions for disease prevention among humans and animals. In veterinary medicine, vaccination has proven to be a boon for animal health. Diseases such as diarrhoea, swine influenza, porcine reproductive and respiratory virus (PRRSV), porcine circovirus associated disease (PCVAD), have been greatly reduced from spreading endemic in several cases. Some diseases such as foot and mouth disease and cholera high fever in swines have been significantly eliminated in North America with the help of vaccination. 

The market for porcine vaccine in the region is expected to exhibit healthy growth in the next few years as well. The rising demand for meat and gelatin and concerns regarding the rising pace of occurrence of zoonotic diseases will be the key factors driving the market in the near future. Transparency Market Research estimates that the North America porcine vaccine market will expand at a 5.3% CAGR from 2016 to 2024. As a result, the market, which valued at US$540.9 mn in 2015, will rise to US$926.2 mn by 2024. 

Download Complete Healthcare Analytical Brochure: 
http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=16976

Inactivated Vaccines to Remain Most Preferred

In terms of the technology used to develop vaccines, the North America porcine vaccines market has been segmented into inactivated vaccines, live attenuated vaccines, recombinant vaccines, toxoid vaccines, DNA vaccines, and conjugate vaccines. Of these, the segment of inactivated vaccines dominated the market in 2015 and is expected to account for a 53.3% of the North America veterinary vaccine market in 2016. The segment is also expected to exhibit the most promising growth in the near future, expanding at a 6.7% CAGR over the period between 2016 and 2024. 

The segment of live attenuated vaccines will exhibit a strong 5.9% CAGR over the said period. Rise in the number of swine farms, rising prevalence of zoonotic disease, and increase in investments by key players are likely to drive the live attenuated vaccine segment. The DNA vaccine segment is projected to emerge as a high-growth segment owing to rise in demand and increase in R&D investments. DNA vaccines have shown excellent results in granting strong immunity against homologous infections and have a good score in terms of approval from regulatory bodies in the region. As a result, the demand for these vaccines is expected to rise at a healthy pace in the region over the forecast period.

U.S. Market to Continue to Account for Dominant Chunk in Sales

The North America porcine vaccine market has been examined for two countries in the region: the U.S. and Canada. The U.S. market for porcine vaccines accounted for a larger 63% share in the North America market in 2015. The U.S. porcine vaccine market is expected to exhibit the most lucrative 6.6% CAGR over the period between 2016 and 2024. Factors such as well-established infrastructure in immunological research, high concentration of key players, highly organized farming structure, increased demand for animal protein, and rising expenditure on animal health by farm owners are attributed to the dominant share of the country in the North America market. 

The market in Canada is also anticipated to expand at a healthy, but comparatively lower CAGR of 5.8% from 2016 to 2024. Factors such as the rising prevalence of PRRS virus and PCV2 among herds and rising focus of key players on R&D activities for the development of effective vaccines will contribute to the growth prospects of the Canada porcine vaccines market in the near future. Moreover, export and import permits among contract manufacturers or distributer firms and low estimated cost of products are also expected to make the porcine vaccine market more popular in Canada. 

Some of the key players in the market are Bayer AG., Bimeda Animal Health, Boehringer Ingelheim GmbH, Ceva Santé Animale, Merck & Co., Inc., Merial (Sanofi), Vetoquinol, Zoetis, Inc., Elanco (Eli Lilly and Company). 

Browse Full Research Report on Porcine Vaccine Market:
http://www.transparencymarketresearch.com/north-america-porcine-vaccine-market.html

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We have an experienced team of Analysts, Researchers, and Consultants, who us e proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Global Medical Education for Neurology Training Market Revenue and Forecast 2024

Medical Education Market: Snapshot

The medical education market is set to boom in the near future thanks to major advances made in the field of medical science, the surging incidence of chronic illnesses, increased incidences of various types of cancer, technological innovations, and the frequent introduction of new courses. The online learning space has grown manifold, especially in developed countries, owing to the growth of the online education market, the increased preference of updated and diverse courses, the development of new start-ups, and higher internet penetration.

Transparency Market Research predicts that the global medical education market is poised to expand at a 4.3% CAGR during the forecast period, rising from a value of US$25.9 bn in 2015 to US$38.4 bn by 2024.

Download Exclusive Global Strategic Business Report:
http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=517

Rising Incidence of Cardiovascular Diseases Spurs Cardiothoracic Education and Training

Medical education includes training in a number of disciplines, including cardiothoracic, neurology, orthopedic, oral and maxillofacial, pediatric, radiology, and laboratory. The cardiothoracic training segment led the medical education market in 2015 by revenue, driven by the rising incidence of cardiovascular diseases, especially coronary blockages. The effectiveness of cardiothoracic training in treating these diseases and curbing side effects such as thrombosis and restenosis associated with a percutaneous coronary intervention (PCI) has also fueled the growth of this segment. Other factors that drive the cardiothoracic training segment are the effective management of heart diseases, rising awareness among patients, and increased medical needs such as surgeries and diagnosis. The radiology training segment is likely to expand at the highest CAGR during the forecast period

Technological Innovations and Upgrades Driving Medical Education in North America and Europe

Geographically, the medical education market has been segmented into North America, Europe, Asia Pacific, and the Rest of the World.

North America was the leading market for medical education in 2015, followed by Europe. Being a well-established region in terms of medical education and healthcare, North America is likely to retain its dominant share throughout the forecast period. The medical education market offers immense growth potential in this region due to timely technological upgrades, increased awareness among patients, and the continuous evolution of information technology.

The growth of the medical education market in Europe is attributed to technological innovations, the consistent introduction of new courses, and increasing healthcare expenditure. In addition, the increased implementation of picture archiving and communication systems (PACS) and stable healthcare education policies widens the scope for growth and acceptance of medical education in this region.

Asia Pacific has been witnessing increased adoption of online training for medical education. Rapidly evolving healthcare infrastructure, the rising number of researchers in the medical field, several initiatives taken by government organizations to provide scholarships and economic relief to medical students, and the presence of a large pool of patients suffering from various types of cancers and cardiovascular diseases in countries such as India and China are some of the key factors driving the medical education market in Asia Pacific.

Apollo Hospitals, TACT Academy for Clinical Training, Zimmer Biomet Holdings, Inc. (Zimmer Institute), Olympus Corporation, Gundersen Health System, GE Healthcare, and Medical Training College are some of the leading players in the global medical education market. 

Browse Full Research Report on Medical Education Market:
http://www.transparencymarketresearch.com/medical-education-market.html

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We have an experienced team of Analysts, Researchers, and Consultants, who us e proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Global Kaposi Sarcoma Market, By Type of Treatment Snapshot in 2024

The global market for Kaposi sarcoma is projected to expand at a modest 2.2% CAGR from 2016 to 2024, with the opportunity in the market rising from US$118.5 mn in 2015 to be worth US$143.2 mn by the end of the forecast period. Hospitals formed the leading distribution channel in 2015, generating over US$40 mn revenue that year. The segment is also slated emerge as the fastest growing segment in the KS market, expanding at a 2.6% CAGR from 2016 to 2024.

Request a PDF Brochure with Report Analysis:
http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=3354

Kaposi sarcoma is a soft tissue sarcoma that develops in connective tissues, blood vessels, fibrous tissues, and muscles. It is a malignant, multi-centric, neoplastic vascular proliferation, characterized by the development of bluish-red cutaneous nodules on the feet. According to the U.S. Center for Disease Control and Prevention (CDC), Kaposi sarcoma is considered an acquired immune deficiency syndrome (AIDS) defining disease. This report analyzes the current and future prospects of the Kaposi sarcoma market based on type of treatment, distribution channel, and geography.

The report is a combination of primary and secondary research, conducted for understanding and arriving at trends, used to forecast the expected revenue of major Kaposi sarcoma therapies in the near future. Primary research formed the bulk of our research efforts with information collected from in-depth interviews and discussions with a number of key industry experts and opinion leaders. Secondary research involved study of company websites, annual reports, press releases, investor presentations, and various international and national databases. The report provides estimated market size in terms of US$ Mn for each treatment method, distribution channel, and geography for the period 2014 to 2024, considering the macro and micro environmental factors. The revenue generated from each treatment method was calculated by considering number of patients, average cost of the drugs, trends in the industry, distribution channel trends, and adoption rate of therapy across all the geographies. The revenues generated from services, including surgery and radiation therapy were calculated based on the costs and average number of procedures.

The market report comprises an elaborate executive summary, which includes a market snapshot that provides information about various segments of the market. It also provides information and data analysis of the market with respect to market segments based on type of treatment, distribution channel, and geography. The market overview section of the report analyzes market dynamics such as drivers, restraints, and opportunities that influence the Kaposi sarcoma market in the current and future scenario. The report provides the list of drugs in various stages of clinical trials, which are expected to shape the future course of the market, through pipeline analysis. The report also provides value chain analysis of the market that describes the sequence of activities from drug manufacturing to the final destination, which is the end user.

Market share analysis is provided to highlight percentage share of the major players operating in the market. All these factors will help market players to decide business strategies and plans to strengthen their position in the global market. Based on geography, the market has been analyzed for major regions: North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. Market forecast for major countries in these regions have also been provided for the forecast period.

In addition, this report includes a list of recommendations to aid new entrants and established players in taking strategic initiatives to strengthen their presence in the market. The report also profiles the major players in the market and provides various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. Major companies profiled in the Kaposi sarcoma market report are Bristol - Myers Squibb, Eli Lilly and Co., Hoffman-La Roche, Inc., GlaxoSmithKline plc, Johnson & Johnson, Pfizer, Inc., and Schering Plough Corporation (Merck & Co., Inc.)

Browse Full Research Report on Kaposi Sarcoma Market:
http://www.transparencymarketresearch.com/kaposis-sarcoma-market.html

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We have an experienced team of Analysts, Researchers, and Consultants, who us e proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

With Increased Fragmentation, U.S. Market for Bacterial Conjunctivitis Drugs to Face Major Setback in Profits

​The U.S. market for bacterial conjunctivitis drugs has been declining sharply over the last few years. Analysts project the trend to continue in the coming years. In 2013, the market’s opportunity was valued at US$473.3 mn, which is likely to reduce to US$439.8 mn by 2024. In the coming years, the market will have to experience a patent cliff as the top U.S. brands of bacterial conjunctivitis drugs, such as AzaSite, Zymaxid, Moxeza, and Vigamox, are set to lose their marketing exclusivity very soon.

Download exclusive Sample of this report:
http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=12323

The growing genericization of antibacterial drugs has impacted the demand for branded drugs significantly. The generic versions of patented formulations, with almost same efficiency as the latter, are easily available at much lower rates in the market. This has increased the sales volume, albeit at the cost of revenues. Many branded ophthalmic drug manufacturers have incurred huge losses due to the generic cannibalization in this market.

Rising Prevalence of MDROs Creates Serious Challenge for Market’s Growth

Apart from this, the rising prevalence of multi-drug resistant organisms (MDROs), triggered by wide usage of antibiotics, incorrect drug dosage, and inappropriate medications, has created serious challenges for the treatment of infections such as bacterial conjunctivitis. Researchers across the world are working on discovering efficient drugs for these MDROs. However, the non-availability of effective medications in near future is likely to hamper the market’s growth over the coming years.

Although the market is facing a number of restraints at present, it may experience a little relief in future if the product development partnerships (PDPs) models for business are implemented by participants. As various research and development procedures incur a high amount, exerting substantial pressure on pharma companies, strategic alliances with small biotech research organizations will prove to be beneficial for both the parties.

Market Encroachment by Generic Variations to Limit Demand for Topical Fluoroquinolones

Fluoroquinolones, macrolides, and aminoglycosides are the major classes of drugs used for the treatment of bacterial conjunctivitis. The demand for topical fluoroquinolones is the highest among all classes of bacterial conjunctivitis drugs in the U.S. However, the segment is projected to be hindered severely in the coming years, owing to the forthcoming patent expirations of bestselling drugs of this class, such as Vigamox, Moxeza, and Zymaxid by the end of 2016.

The market’s opportunity will also be hurt significantly over the next few years due to the encroachment by generic variations of these drugs and decline from US$361.9 mn in 2013 to US$286.4 mn by 2024.

Imminent Patent Expiries to Hurt Leading Players Severely

Valeant Pharmaceuticals Int. Inc., Santen Pharmaceutical Co. Ltd., Pfizer Inc., Perrigo Com. Plc., Novartis AG, Merck & Co. Inc., F. Hoffmann-La Roche Ltd., Bayer AG, Akorn Inc., and Actavis Plc. are leading the market for bacterial conjunctivitis drugs in the U.S. The imminent patent expiries is likely to hurt the business of these players significantly in the near future. However, the rising prevalence of bacterial infection in eyes and the increasing susceptibility to infection among individuals of various age groups may provide rewarding opportunities to participants over the next few years.

Players are recommended to focus on developing herbal medicines for the treatment of bacterial conjunctivitis, as the consumer preference is shifting from pharmacological medicines to herbal treatment regimens.

Browse Full Research Report on Bacterial Conjunctivitis Drugs Market:
http://www.transparencymarketresearch.com/us-bacterial-conjunctivitis-drugs-market.html

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We have an experienced team of Analysts, Researchers, and Consultants, who us e proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Single-use Bioprocessing Systems Market Asia Pacific and North America to Lead Market Growth during Forecast Period

Transparency Market Research has published a new market report titled, “Single-use Bioprocessing Systems Market: (By Product – Bioreactors & Fermenters, Mixers, Bags, Bioprocess Containers, Filtration Devices, Tubing, Sampling Systems, Connectors & Clamps, Probes & Sensors; By End-user – Pharmaceutical, Biotechnology, CRO & CMO, and Academic & Research Institutes; By Application – Monoclonal Antibody Production, Vaccine Production, Plant Cell Cultivation, Patient Specific Cell Therapies, and Others) – Global & North America Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2016–2024.” According to the report, the global single-use bioprocessing systems market was valued at US$ 2,356.8 Mn in 2015 and is projected to expand at a CAGR of 11.1% from 2016 to 2024 to reach US$ 5,914.6 Mn in 2024. This report offers a thorough understanding of the global single-use bioprocessing systems market, its key trends, drivers, restraints, opportunities and threats.

Download Exclusive Global Strategic Business Report:
http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=3753

Single-use bioprocessing systems are disposable equipment and consumables used in research and development as well as commercial production of biological drugs and metabolites. The adoption of single-use bioprocessing systems has seen a paradigm shift in recent years compared to its market over a decade ago. This implies that until recently, bio-production facilities relied on the use of fixed and non-portable stainless steel equipment such as large bioreactors and tanks to culture large volumes of fluid and hold buffers. However, currently, there is a growing acceptance of single-use technologies across the manufacturing process. Technological developments have enabled continuous single-use manufacturing a possibility, driven by the fact that several features of single-use bioprocessing products are continually evolving and improving.

In terms of market share, North America and Europe dominated the single-use bioprocessing systems market in 2015 and are projected to retain their dominant position during the forecast period from 2016 to 2024. This leadership position can be attributed to the fact that CRO’s & CMO’s, and niche biotechnology and multiproduct biopharmaceutical organizations in this region have been early adopters of single-use technologies compared to their counterparts in the emerging markets. The leadership in terms of revenue share is likely to sustain due to cutting edge research and development in biologics being centered in these regions globally. It has been postulated that the purchase of single-use systems would be higher in regions which lay greater emphasis on innovation and in regions where developments in bioscience are clustered. Moreover, many leading vendors are headquartered in North America and Europe, where they have higher share of product sales. Of the top 10 best-selling biological drugs of 2014, five were monoclonal antibodies, four were recombinant proteins, and one was a vaccine. This trend directly percolates to the application segment of the single-use bioprocessing systems market. For instance, in 2015, the highest revenue gaining application segment in both Europe as well as North America was monoclonal antibodies production followed by ‘others’ segment which includes recombinant proteins and enzymes. Together, these segments accounted for over 67% share in North America and over 71% share in Europe of the single-use bioprocessing systems market in 2015.

The pharmerging region of Asia Pacific has a booming biotechnology and biopharmaceutical industry. Moreover, many pharmaceutical organizations are providing contract research services to CRO’s & CMO’s in India and China. Furthermore, many countries in Asia Pacific have a higher cancer and infectious disease burden than the developed world, which implies that the disease burdened population is at a higher need for new cancer therapies and vaccines. Single-use bioprocessing systems will aid to address the unmet needs for a population which requires medicines that are cheaper and take reduced time to market. Driven by the booming biopharmaceutical and contract manufacturing sector and coupled with greater therapeutic needs of the population, the single-use bioprocessing systems market in Asia Pacific is set to expand at a rate higher than the global average during the forecast period from 2016 to 2024. This is attributable to the market seeing an influx of single-use vendors opening offices in countries in Asia Pacific for enhancing business in this region. For instance, in January 2015, Finesse Solutions opened a subsidiary office in Shanghai to serve the active Chinese market for single-use bioprocessing systems, as well as serve major areas of biotech expansion such as Seoul, Tokyo, and Singapore.

Collectively, Latin America and Middle East & Africa contributed to over 23% of the global market share for single-use bioprocessing systems in 2015. The market in these regions has not yet picked up pace as Europe, North America, and Asia Pacific; however, the proximity to North America coupled with increase in contract manufacturing activities is expected to drive the rise in adoption of single-use bioprocessing systems in these markets. A gradually rising biotechnology sector in the UAE as well as South Africa would propel the market for single-use technologies in these countries. However, a skills gap exists in these countries due to which the adoption of single-use technologies may face a restraint during the forecast period. Overall, the MEA and LATAM markets are likely to grow at a rate less than the global average due to late adoption of single-use systems. Despite this, the benefit of cost savings and rapid research would augment market growth in these regions during the period from 2016 to 2024.

Thermo Fisher Scientific, Merck KGaA (Merck Millipore), Danaher Corporation (Pall Corporation), Sartorius AG, Eppendorf AG, GE Healthcare, PBS Biotech, Inc., Meissner Filtration Products, Inc., Finesse Solutions, Sentinel Process Solutions, and Saint-Gobain are the key players operating in this market.

Browse Full Research Report on Single-use Bioprocessing Systems Market:
http://www.transparencymarketresearch.com/single-use-bio-processing-systems-market.html

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We have an experienced team of Analysts, Researchers, and Consultants, who us e proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Radiofrequency Ablation Devices for Pain Management Market: Consumer Preference for Minimally Invasive Pain Management Options to Boost Growth Opportunities

The radiofrequency ablation devices for pain management market features a markedly high level of consolidation, with the top three vendors,  St. Jude Medical, Inc., Halyard Health, Inc., and Boston Scientific Corporation, accounting for a share of over 88% in 2015, observes Transparency Market Research. “These companies have strengthened their hold on the market owing to diversified product portfolios, extensive geographical presence, and strategic acquisitions over the past few years,” states a TMR analyst. Increased focus on emerging economies and increase in product launches are some of the most popular strategies adopted by top players.

Transparency Market Research states that the global radiofrequency ablation devices for pain management market, which valued at US$372.7 mn in 2015, is expected to rise to US$1,114.5 mn in 2024. This translates to a potential 13.0% CAGR over the period between 2016 and 2024.

Download Exclusive Global Strategic Business Report:
http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=985

In terms of product varieties, the segment of disposable RF products dominated, accounting for a 40% of the overall market in 2015. The segment of RF generators is expected to exhibit expansion at the most promising pace over the forecast period. From a geographic perspective, the market in North America dominated in 2015, accounting for over 40% of the global market in 2015. However, the global market is expected to witness most lucrative growth opportunities in emerging economies across regions such as Asia Pacific and Latin America over the forecast period.

Rising Prevalence of Chronic Pain to Have Sizeable Positive Impact on Market Growth

The rising prevalence of chronic pain conditions and the rising geriatric population of the world are among the key factors leading to the rising global demand for pain management therapies such as the ones that use radiofrequency ablation devices. The global market for these devices for pain management is also highly influenced by the rising demand for minimally invasive procedures across the globe.

Benefits such as lesser post-surgery complications, low chances of side effects, and shorter span of recovery work in favor of minimally invasive surgeries and related devices. Radiofrequency ablation devices for pain management are also gaining increased focus owing to the higher known side effects and lower efficiency of alternate pain relief procedures and therapeutics options such as acupressure, acupuncture, and opioids. The easy availability, cost-effectiveness, and easy access to highly effective radiofrequency ablation devices for pain management have also propelled the market for these devices of late.

Regulatory Hurdles Delaying Approval of New Devices to Hamper Market Growth

The need to comply with stringent laws and regulations set by regulatory authorities that are closely associated with product approvals, clinical trials, design, development, and commercialization hamper the overall development of the market to a sizable extent. Ablation devices come under class III medical device category in Europe and the U.S. Owing to this, the efficacy and safety of devices such as catheters and generators are paramount to gain approval. Strict regulations do not only delay approval, launch, and marketing of these products but also lead to increased prices.

Decisions of regulatory authorities and cost containment measures undertaken by government authorities also have a negative impact on the reimbursement scenario and restrain the market for radiofrequency ablation devices for pain management. Along with these factors, the low costs of several pain management therapeutic options such as anticonvulsants, antidepressants, and NSAIDs also significantly impact and restrain the overall development of the global radiofrequency ablation devices for pain management market.

This review of the market is based on a market research report recently published by Transparency Market, titled “Radiofrequency Ablation Devices for Pain Management Market (Product - RF Generators, Reusable Products, and Disposable Products; End-user - Specialty Clinics, Ambulatory Surgical Centers, and Hospitals) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024.”

Browse Full Research Report on Radiofrequency Ablation Devices for Pain Management Market: 
http://www.transparencymarketresearch.com/radiofrequency-ablation-devices.html

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We have an experienced team of Analysts, Researchers, and Consultants, who us e proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.